Merus NV

Xencor Inc

Zymeworks Inc

zenocutuzumab — NRG1 fusion+ NSCLC/PDAC

175 PubMed publications found for Merus NV

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

174 PubMed publications found for Merus NV

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

173 PubMed publications found for Merus NV

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.

171 PubMed publications found for Merus NV

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

168 PubMed publications found for Merus NV

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.

169 PubMed publications found for Merus NV

167 PubMed publications found for Merus NV

<article class="bts-verified-summary" data-ticker="MRUS">
<p>Merus NV (MRUS) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for MRUS were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22MRUS%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR

Merus NV (MRUS) — BioTechSigns Verified Summary

Merus NV (MRUS) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for MRUS were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22MRUS%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11